by David Brindley | Sep 9, 2014
. With contributions from James Smith, a recent Oxford University graduate and current SENS Research Foundation Summer Scholar working at the Harvard Stem Cell Institute. ‘Bay Area biotechnology’ is a description that conjures images of the proud Hoover Tower...
by Mark Curtis | Aug 18, 2014
. Welcome to your Update from the Clinic for the month of July. The cancer stem cell companies were back in the news last month. OncoMed initiated its ALPINE clinical trial of Tarextumab for pancreatic cancer, while Stemline Therapeutics announced an investigational...
by Mark Curtis | Aug 11, 2014
. Welcome to your deal review for the month of July. There was financing activity this past month as StemCells and Fate Therapeutics each secured $20 million in funding. Bluebird bio was busy with the acquisition of a privately-held genome editing company; clearly a...
by Stacey Johnson | Jul 25, 2014
. It’s nice to end the week on a happy note. For a company like CCRM that commercializes regenerative medicine products and therapies, the news that ViaCyte, a company based in San Diego, California, has applied to the FDA to start clinical trials for its Type 1...
by Mark Curtis | Jul 21, 2014
. The Centre for Commercialization of Regenerative Medicine (CCRM) just finished hosting the 7th annual Business of Regenerative Medicine course here in Toronto, which saw many notable figures in the space come to weigh-in on a number of critical issues relevant to...
by Mark Curtis | Jul 9, 2014
. Welcome to your Update from the Clinic for the month of June. Neuralstem presented final data on a first-in-class drug for the treatment of major depressive disorder, which is proving to be an effective and non-invasive means to boost brain volume. OncoMed has a...
Comments